List All Sarcoma Trials

Sarcoma

 

Eribulin or Dacarbazine for Leiomyosarcoma and Liposarcoma (UW11016)
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Investigator: Robin L. Jones, MD;   Conditions: Soft Tissue Sarcoma;    Status: Closed;   Study ID: NCT01327885

Ramucirumab + Docetaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01567163

Ramucirumab + Paclitaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01515306

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma (2705)
A Pilot Study To Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma

Investigator: Seth Pollack;   Conditions: Sarcoma; Solid Tumors;    Status: Recruiting;   Study ID: NCT01957709

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Closed;   Study ID: NCT02122861

NY-ESO-1-specific T Cells for Metastatic NY-ESO-1-Expressing Sarcomas (2721)
A pilot trial of NY-ESO-1-specific T cells in patients with metastatic NY-ESO-1-expressing sarcomas receiving palliative radiation

Investigator: Seth Pollack;   Conditions: Sarcoma;    Status: Recruiting;   Study ID: NCT02319824

PLX3397 for Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath (20151460)
A Double-Blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

Investigator: Elizabeth Loggers, MD;   Conditions: Giant Cell Tumors; Solid Tumors;    Status: Recruiting;   Study ID: NCT02371369

Oral Regorafenib for Refractory Liposarcoma, Osteosarcoma, and Ewing Sarcomas (20132286)
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

Investigator: Elizabeth Loggers, MD;   Conditions: Sarcoma; Liposarcoma; Sarcoma, Ewing; Osteosarcoma;    Status: Recruiting;   Study ID: NCT02048371

CMB305 and Atezolizumab for Sarcoma (9521)
A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Investigator: Seth Pollack, MD;   Conditions: Sarcoma; Liposarcoma;    Status: Recruiting;   Study ID: NCT02609984